The FDA is launching a pilot program using AI and cloud computing to monitor clinical trials in real time. This shift aims to accelerate drug approval timelines by replacing manual oversight with automated data streams. The move follows recent DOGE layoffs. Practitioners can expect faster regulatory feedback loops and tighter data compliance requirements.